Concepedia

Pascal Rigollier

PR

16

Publications

1.4K

Citations

14

H-Index

1990

Active since

Affiliations

Novartis (Switzerland)(Current)

Novartis Institutes for BioMedical Research

Novartis (United States)

Genomics Institute of the Novartis Research Foundation

Synaptic Research (United States)

Pascal Rigollier is an author at Novartis (Switzerland) specializing in medicine, pharmacology, and drug discovery.

Top concepts

Publications per year

1990–2022

16

Publications

16

Structure-based design of aliskiren, a novel orally effective renin inhibitor

Jeanette M. Wood, Jürgen Maibaum, Joseph Rahuel et al. · Biochemical and Biophysical Research Communications · 2003 · 502 citations

, , +7

Food intake in free-feeding and energy-deprived lean rats is mediated by the neuropeptide Y5 receptor.

Leoluca Criscione, Pascal Rigollier, Christine Batzl‐Hartmann et al. · Journal of Clinical Investigation · 1998 · 227 citations · Full text

, , +22

Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C

Andreas Weiss, Edwige Lorthiois, Louise Barys et al. · Cancer Discovery · 2022 · 130 citations · Full text

Structural Modification of the P2‘ Position of 2,7-Dialkyl-Substituted 5( <i>S</i> )-Amino-4( <i>S</i> )-hydroxy-8-phenyl-octanecarboxamides:  The Discovery of Aliskiren, a Potent Nonpeptide Human Renin Inhibitor Active after Once Daily Dosing in Marmosets

Jürgen Maibaum, Stefan Stutz, Richard Göschke et al. · Journal of Medicinal Chemistry · 2007 · 95 citations · Full text

JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRAS<sup>G12C</sup> for the Treatment of Solid Tumors

Edwige Lorthiois, Marc Gerspacher, Kim S. Beyer et al. · Journal of Medicinal Chemistry · 2022 · 84 citations · Full text

Rows per page

1–5 of 16